Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations Meeting Abstract
| Authors: | Garmezy, B.; Borad, M.; Lin, C. C.; Chen, L. T.; Perez, C. A.; Kato, S.; Tam, B.; Severson, P.; Quah, C. S.; Harding, J. J. |
| Abstract Title: | Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S231 |
| End Page: | S232 |
| Language: | English |
| ACCESSION: | WOS:001087480200127 |
| DOI: | 10.1016/j.annonc.2023.09.1423 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 130P -- Source: Wos |
